[go: up one dir, main page]

WO2010022055A3 - 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders - Google Patents

1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders Download PDF

Info

Publication number
WO2010022055A3
WO2010022055A3 PCT/US2009/054169 US2009054169W WO2010022055A3 WO 2010022055 A3 WO2010022055 A3 WO 2010022055A3 US 2009054169 W US2009054169 W US 2009054169W WO 2010022055 A3 WO2010022055 A3 WO 2010022055A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
chronic pain
pain disorders
derivatives useful
ine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/054169
Other languages
French (fr)
Other versions
WO2010022055A2 (en
Inventor
John L. Buchanan
Howard Bregman
Nagasree Chakka
Erin F. Dimauro
Bingfan Du
Hanh Nho Nguyen
Xiao Mei Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of WO2010022055A2 publication Critical patent/WO2010022055A2/en
Publication of WO2010022055A3 publication Critical patent/WO2010022055A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides compounds that are inhibitors of voltage-gated sodium channel (Nav), in particular Nav 1.7 and are therefore useful for the treatment of diseases 5 treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
PCT/US2009/054169 2008-08-20 2009-08-18 Inhibitors of voltage-gated sodium channels Ceased WO2010022055A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18950108P 2008-08-20 2008-08-20
US61/189,501 2008-08-20
US19601208P 2008-10-14 2008-10-14
US61/196,012 2008-10-14

Publications (2)

Publication Number Publication Date
WO2010022055A2 WO2010022055A2 (en) 2010-02-25
WO2010022055A3 true WO2010022055A3 (en) 2010-06-17

Family

ID=41707632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/054169 Ceased WO2010022055A2 (en) 2008-08-20 2009-08-18 Inhibitors of voltage-gated sodium channels

Country Status (1)

Country Link
WO (1) WO2010022055A2 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
ES2533990T3 (en) * 2010-02-24 2015-04-16 Research Triangle Institute Arylpiperazine opioid receptor antagonists
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels
US8486647B2 (en) 2010-06-09 2013-07-16 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
CN102344407A (en) * 2010-08-03 2012-02-08 艾琪康医药科技（上海）有限公司 3-droperidol derivative and preparation method thereof
HRP20160094T1 (en) * 2010-09-13 2016-02-26 Novartis Ag Triazine-oxadiazoles
EP2681193B1 (en) 2011-03-02 2016-01-06 Lead Discovery Center GmbH Pharmaceutically active disubstituted pyridine derivatives
CA2826464C (en) 2011-03-02 2020-07-28 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
CN102285969B (en) * 2011-06-28 2013-06-19 山东大学 N-1-substituted piperidin-4-arylamine derivatives and preparation method and use thereof
KR20140105445A (en) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. Biaryl ether sulfonamides and their use as therapeutic agents
BR112014010271A2 (en) 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc benzenesulfonamide compounds and their use as therapeutic agents
PE20150400A1 (en) 2012-05-22 2015-03-27 Genentech Inc N-SUBSTITUTED BENZAMIDES AND ITS USE IN THE TREATMENT OF PAIN
CA2878478A1 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
US9040712B2 (en) * 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
WO2014127116A1 (en) 2013-02-13 2014-08-21 Novartis Ag Topical ocular analgesic agents
JP6096370B2 (en) 2013-03-14 2017-03-15 ジェネンテック， インコーポレイテッド Substituted triazolopyridines and methods of use
JP6227112B2 (en) 2013-03-15 2017-11-08 ジェネンテック， インコーポレイテッド Substituted benzoxazole and methods of use
EP2970231A1 (en) 2013-03-15 2016-01-20 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
EP3039019B1 (en) * 2013-08-26 2020-04-22 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
US20160237071A1 (en) * 2013-10-02 2016-08-18 Nissan Chemical Industries, Ltd. T-type calcium channel inhibitor
EP3409674B1 (en) 2013-10-17 2022-04-06 Blueprint Medicines Corporation Process for preparing compositions useful for treating disorders related to kit
WO2015058129A1 (en) * 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
CN106103422B (en) * 2014-02-12 2020-09-18 普渡制药公司 Isoquinoline derivatives and their uses
PE20161368A1 (en) * 2014-03-17 2016-12-25 Pfizer DIACILGLICEROL ACILTRANFERASE 2 INHIBITORS
CN104016977B (en) * 2014-06-13 2016-06-22 山东大学 A kind of replacement thiadiazine diketone derivative and preparation method thereof and application
CN106715418A (en) 2014-07-07 2017-05-24 基因泰克公司 Therapeutic compounds and methods of use thereof
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AU2016268120A1 (en) 2015-05-22 2017-11-30 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2018521076A (en) 2015-07-24 2018-08-02 ブループリント メディシンズ コーポレイション Compounds useful for treating diseases associated with KIT and PDGFR
JP2018526371A (en) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド Therapeutic compounds and methods of use thereof
WO2017058821A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
CN105837525B (en) * 2016-03-25 2019-05-28 浙江工业大学 2, 4-diamine-1, 3,5-triazine compound and preparation method and application thereof
JP2019513714A (en) 2016-03-30 2019-05-30 ジェネンテック， インコーポレイテッド Substituted benzamides and methods of use thereof
CA3039853A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN110099898B (en) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 Compounds and uses thereof
FI3541784T3 (en) 2016-11-18 2023-10-02 Integrative Res Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
EA037318B1 (en) 2016-12-16 2021-03-11 Пфайзер Инк. Glp-1 receptor agonists and uses thereof
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
WO2018175707A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN106995380B (en) * 2017-03-31 2018-12-28 九江善水科技股份有限公司 A kind of synthetic method of 2- Amino-4-nitrophenol
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
WO2019018795A1 (en) * 2017-07-20 2019-01-24 Yumanity Therapeutics Compounds and uses thereof
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
CN112312913B (en) 2018-03-23 2024-03-08 詹森药业有限公司 Compounds and their uses
WO2019191702A1 (en) 2018-03-30 2019-10-03 F. Hoffmann-La Roche Ag Substituted hydro-pyrido-azines as sodium channel inhibitors
JP2021522253A (en) 2018-04-25 2021-08-30 ユマニティ セラピューティクス，インコーポレーテッド Compounds and their use
TW202003490A (en) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 Therapeutic compounds and methods of use thereof
AU2020212034A1 (en) 2019-01-24 2021-09-16 Janssen Pharmaceutica Nv Compounds and uses thereof
EP3856341B1 (en) 2019-04-12 2023-09-06 Blueprint Medicines Corporation Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
MX2021012469A (en) 2019-04-12 2022-01-18 Blueprint Medicines Corp Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases.
EA202192047A1 (en) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS
CN111057021B (en) * 2019-12-11 2023-05-23 中国药科大学 s-triazine compound and its preparation method and use
NZ788624A (en) * 2019-12-23 2025-08-29 Lg Chemical Ltd Novel amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof
ES2969310T3 (en) * 2019-12-23 2024-05-17 Lg Chemical Ltd New amide derivative useful as a diacylglycerol acyltransferase 2 inhibitor, and use thereof
JPWO2023132208A1 (en) * 2022-01-07 2023-07-13
WO2023229685A2 (en) * 2022-02-24 2023-11-30 Microbiotix, Inc. Broad-spectrum inhibitors of cytomegalovirus
CN116178465A (en) * 2023-03-06 2023-05-30 中国科学院成都生物研究所 Four-membered ring-containing polyphenol compound and application thereof
AU2024289298A1 (en) 2023-07-06 2026-01-15 Integrative Research Laboratories Sweden Ab Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof
CN117384091B (en) * 2023-12-08 2024-02-20 四川大学华西第二医院 Amide derivative, synthesis method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083653A1 (en) * 2001-04-11 2002-10-24 Amgen Inc. Triazinyl acrylamide derivatives as kinase inhibitors
WO2002092576A1 (en) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083653A1 (en) * 2001-04-11 2002-10-24 Amgen Inc. Triazinyl acrylamide derivatives as kinase inhibitors
WO2002092576A1 (en) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents

Also Published As

Publication number Publication date
WO2010022055A2 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
WO2010022055A3 (en) 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders
WO2009012242A3 (en) Sodium channel inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
IL196543A (en) Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
WO2010017545A3 (en) Triazole compounds that modulate hsp90 activity
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2008135826A3 (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
WO2007021941A3 (en) Inhibitors of voltage-gated sodium channels
WO2008089307A3 (en) Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
MX346186B (en) Protein kinase inhibitors.
WO2008147797A3 (en) Ion channel modulators and methods of use
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2009076454A3 (en) Compounds that modulate intracellular calcium
WO2008070016A3 (en) Inhibitors of akt activity
MX2009008253A (en) Kinase inhibitors.
WO2006135627A3 (en) Inhibitors of akt activity
WO2009036996A3 (en) Small molecule bradykinin b1 receptor antagonists
WO2005046603A3 (en) Pyridine compounds
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
WO2010042925A3 (en) Compositions and methods for treating alcohol use disorders, pain and other diseases

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09791616

Country of ref document: EP

Kind code of ref document: A2